Valneva Se (VALN) has released an update.
Valneva SE has reported a strong first quarter in 2024 with total revenues of €32.8 million and a net profit of €58.9 million, largely due to the sale of a Priority Review Voucher. The company affirmed its revenue forecast for the year to be between €170 and €190 million, driven by the growth of its proprietary products. Valneva also highlighted progress in its product pipeline, including the chikungunya vaccine IXCHIQ®’s recommendation by ACIP, ongoing Phase 3 trials for its Lyme disease vaccine, and initiation of a Phase 1 trial for a second-generation Zika vaccine.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
